Q/C Technologies, Inc. (QCLS): Total Liabilities
$16.44M
As of 2025-12-31
$3.79M
As of 2026-06-30
+79.5%
3-year compound annual growth
+22.6%
5-year compound annual growth
+25.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.44M | +145.3% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $6.70M | +31.7% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $5.09M | +78.9% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $2.84M | +144.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $1.17M | -80.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $5.93M | +287.9% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $1.53M | -22.5% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $1.97M | +10.6% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $1.79M | +5.2% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $1.70M | +1.7% | 2018-07-13, Balance as of period end |
| 2015-12-31 | $1.67M | -9.5% | 2017-04-11, Balance as of period end |
| 2014-12-31 | $1.84M | -5.6% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $1.95M | n/a | 2015-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Q/C Technologies, Inc. (QCLS) | 2025-12-31 | $16.44M | +145.3% |
| Achieve Life Sciences, Inc. (ACHV) | 2025-12-31 | $20.27M | +14.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $793.1K | -25.0% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $42.49M | +19.7% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
Compare QCLS, ACHV, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗